Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAgronomics Regulatory News (ANIC)

Share Price Information for Agronomics (ANIC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 8.30
Bid: 8.20
Ask: 8.40
Change: 0.12 (1.45%)
Spread: 0.20 (2.439%)
Open: 8.30
High: 8.42
Low: 8.30
Prev. Close: 8.30
ANIC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Additional Participation in BlueNalu Fundraise

19 Dec 2019 07:00

RNS Number : 3540X
Agronomics Limited
19 December 2019
 

19 December 2019

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 ('MAR). Upon the publication of this announcement via a Regulatory Information Service ('RIS'), this inside information is now considered to be in the public domain.

 

Agronomics Limited

 

("Agronomics" or the "Company")

 

Additional Participation in BlueNalu, Inc. Series A Fundraise

 

Agronomics is pleased to announce it has today completed a further subscription of US $1,999,998.00 for 108,108 Series A Preferred Shares (the "Subscription") in BlueNalu, Inc. ("BlueNalu"). This Subscription will increase Agronomic's existing interest to 6.0% (reducing to 5.9% on the expected closing of the ongoing Series A $20m round fully subscribed), accounting for the existing investment of US$ 749,990, that Agronomics made on 29 August 2019 in an earlier close of BlueNalu's Series A fundraise, and Agronomics' Seed investment of US $250,000 in August 2018.

 

The Company now holds 192,005 shares of BlueNalu, comprising 43,357 Seed Preferred Shares and 148,648 Series A Preferred Shares, with a book value of US $3,552,111.

 

During BlueNalu's live product demonstration on 10th December 2019, Lou Cooperhouse, BlueNalu's President & CEO commented: -

 

"Our team has successfully produced whole-muscle portions of yellowtail fish fillet, derived directly from fish cells, in which our product performs the same way as a conventional fish fillet in all cooking applications. Our medallions of yellowtail can be cooked via direct heat, steamed or even fried in oil; can be marinated in an acidified solution for applications like poke, ceviche, and kimchi, or can be prepared in the raw state. This is an enormous accomplishment, and we don't believe that any other company worldwide has been able to demonstrate this level of product performance in a whole-muscle seafood product thus far".

 

Links to the press release, and photos from the event can be found at https://www.bluenalu.com/pr-121719

 

As the Subscription is considered a Substantial Transaction under AIM rules, this announcement requires certain disclosures under Schedule Four of the AIM Rules. BlueNalu is an early stage, pre-revenue company with cash burn rate of US $350,000 per month and net assets as at 31st July 2019 of approximately US $865,000.

 

Richard Reed, Chairman of Agronomics, commented: -

 

"Agronomics is thrilled to have increased its investment in BlueNalu, a consequence of the tremendous efforts and significant milestones the team has achieved in the past few months. We look forward to the exciting pathway ahead for BlueNalu as they move to commercialise their first cultivated seafood products."

 

About BlueNalu

BlueNalu's mission is to be the global leader in cellular aquaculture, providing consumers with great tasting, healthy, safe, and trusted seafood products that support the sustainability and diversity of our ocean. BlueNalu is aligned with 10 of the 17 Sustainable Development Goals (SDG) of the United Nations, a blueprint to achieve a better and more sustainable future for our planet. BlueNalu was founded in 2018 and is based in San Diego, California.

About Agronomics

 

Agronomics is an AIM-listed investment company focused on the nascent field of cellular agriculture and synthetic biology, with an emphasis on environmentally friendly alternatives to the traditional production of animal-derived products. The Company was launched in April 2019, with the appointment of a highly experienced team of investors and entrepreneurs including Richard Reed, Jim Mellon and David Giampaolo.

Agronomics believes that the recent developments within cellular agriculture and the alternative protein space will play a major role in feeding the world's growing population as it approaches 10 billion people by 2050. The production of animal protein via novel approaches is a viable solution to minimise global greenhouse gas emissions, water, energy and land requirements as well as alleviating animal welfare concerns.

 

For further information, please contact: -

Agronomics Limited

Beaumont Cornish Limited

Zeus Capital Limited

Peterhouse Capital Limited

Britton Financial PR

The Company

Nomad

Joint Broker

Joint Broker

Investor Relations

Denham Eke

+44 (0) 1624 639396

Roland Cornish/James Biddle

+44 (0) 207 628 3396

Mike Seabrook

+44 (0) 203 829 5000

Jamie Peel

+44 (0) 161 831 1512

 

Lucy Williams

+44 (0) 207 469 0936

Tim Blackstone

+44 (0) 7957 140416

 

 

ENDS

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCLLFIFFILTLIA
Date   Source Headline
12th Oct 20167:00 amRNSNet Asset Value(s)
22nd Jul 20167:00 amRNSNet Asset Value(s)
29th Apr 20167:00 amRNSNet Asset Value calculation to 31 March 2016
15th Apr 20167:00 amRNSChange of Adviser
18th Mar 20167:00 amRNSHolding(s) in Company
17th Mar 20167:00 amRNSInterim Results for the six months to 31 Dec 2015
10th Feb 201612:11 pmRNSResult of AGM
25th Jan 20167:00 amRNSNet Asset Value(s)
22nd Dec 20157:00 amRNSAnnual Audited Results and Notice of AGM
17th Dec 20154:00 pmRNSDBC receives US FDA approval to market PulseFlowDF
4th Nov 20157:00 amRNSNet Asset Value(s)
30th Jul 20157:01 amRNSNet Asset Value(s)
15th Apr 20157:00 amRNSNet Asset Value as at 31 March 2015
30th Mar 20157:00 amRNSInterim results for 6 months to 31 December 2014
6th Feb 201512:21 pmRNSClose of Tender Offer
4th Feb 20155:36 pmRNSRe Results of Tender Offer
2nd Feb 20158:00 amRNSResults of Tender Offer
23rd Jan 20157:00 amRNSHolding(s) in Company
15th Jan 201511:56 amRNSHolding(s) in Company
14th Jan 20157:00 amRNSTender Offer
12th Jan 20159:32 amRNSNet Asset Value
30th Dec 20147:00 amRNSAnnual audited results
23rd Dec 201411:58 amRNSHolding(s) in Company
28th Nov 20142:04 pmRNSTender Offer in respect of Magna Biopharma
21st Oct 20147:00 amRNSNet Asset Value to 30 September 2014
22nd Jul 20147:00 amRNSNet Asset Value(s)
8th Apr 20147:00 amRNSNet Asset Value calculations to 31 March 2014
31st Mar 20147:00 amRNSInterim Results for the six months to 31 Dec 2013
24th Jan 201411:21 amRNSHolding(s) in Company
20th Jan 201410:56 amRNSHolding(s) in Company
17th Jan 20147:00 amRNSNet Asset Value(s)
15th Jan 20147:00 amRNSAppointment of Nominated Adviser
6th Jan 20145:49 pmRNSHolding(s) in Company
20th Nov 20134:04 pmRNSHolding(s) in Company
13th Nov 20135:13 pmRNSHolding(s) in Company
12th Nov 20137:00 amRNSResult of General Meeting
24th Oct 20137:01 amRNSNotice of General Meeting
24th Oct 20137:00 amRNSAnnual Financial Report
18th Oct 201311:23 amRNSHolding(s) in Company
18th Oct 20137:00 amRNSNet Asset Value(s)
4th Oct 20132:13 pmRNSHolding(s) in Company
26th Sep 20135:10 pmRNSHolding(s) in Company
13th Sep 201311:32 amRNSHolding(s) in Company
6th Sep 20135:29 pmRNSHolding(s) in Company
6th Aug 20139:40 amRNSHolding(s) in Company
11th Jul 20137:00 amRNSNet Asset Value(s)
15th Apr 201312:34 pmRNSDirectorate Change
12th Apr 20132:17 pmRNSHolding(s) in Company
10th Apr 20137:00 amRNSDirector/PDMR Shareholding
9th Apr 20137:00 amRNSNet Asset Value calculation to 31st March 2013

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.